Released Jan 29, 2025, after the close
10-K filed Jan 29, 2025, 90 days after period end · 0001654954-25-000915
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.33M$2.33M derived−35.2% vs Q4 2023−3.5% vs Q3 2024
Net Income$16.11K$16.11K derivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$726,570−21.9%
Operating Incomederived-$154,130N/M
Operating Cash Flowderived$78,425−74.6%
Free Cash Flowderived-$78,590N/M
Margins · derived
Gross margin31.1%+5.3 pt vs Q4 2023
Operating margin-6.6%−5.2 pt vs Q4 2023
Net margin0.7%+2.0 pt vs Q4 2023
What the release said
The release
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $2.33M | $3.60M | $4.64M | $5.60M |
| Net Income | $16.11K | -$47.15K | $173.38K | -$4.87M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR